The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Venetoclax for paediatric acute myeloid leukaemia: a step forward
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, ABT-199 caused less damage to platelets than the second-generation drug ABT-263 in both in vitro and in vivo studies.362–364”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [364]
Citations
Cites
Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer
Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T. I., Yasui, Y., Leisenring, W. M., Stovall, M., Chow, E. J., Sklar, C. A., Mulrooney, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3205 · Cited by 737
Dinardo, C. D., Pratz, K. W., Letai, A. G., Jonas, B. A., Wei, A. H., Thirman, M. J., Arellano, M. L., Frattini, M. G., Kantarjian, H. M., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 723
Dinardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., et al. (2020) · Blood · doi:10.1182/blood.2019003988 · Cited by 681
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., de Bont, E. S. J. M., Moerloose, B. D., Dworzak, M. N., Gibson, B. E. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8289 · Cited by 394
Self-citationKaspers, G. J. L., Zimmermann, M., Reinhardt, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7384 · Cited by 238
Karol, S. E., Alexander, T., Budhraja, A., Pounds, S. B., Canavera, K. E., Wang, L., Wolf, J., Klco, J. M., Mead, P. E., Gupta, S. D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30060-7 · Cited by 165
Gorman, M. F., Ji, L., Ko, R. H., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22612 · Cited by 112
Getz, K., Sung, L., Ky, B., Gerbing, R. B., Leger, K. J., Leahy, A. B., Sack, L., Woods, W. G., Alonzo, T. A., Gamis, A. S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00313 · Cited by 102
Self-citationFleischhack, Hasan, Graf, N. M., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00836.x · Cited by 98
Cooper, T. M., Absalon, M. J., Alonzo, T. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.10003 · Cited by 11
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Metadata
- Authors
- Aplenc, R.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Aplenc, Richard
- ORCID
- Aplenc, Richard
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 476-478
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3011438422
- Cited by
- 1
- References
- 10
- Citations by year
- 2023: 1
- FWCI
- 0.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- venetoclax, pediatric acute myeloid leukemia, BCL-2 inhibitor, cytarabine, idarubicin, intensive chemotherapy, dose escalation, combination therapy, decitabine, azacitidine, elderly patients
- MeSH terms
- Child, Cytarabine, Humans, Sulfonamides, Idarubicin, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
